Leniolisib for Immune Dysregulation in CVID
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 20
- Registration Number
- NCT06897358
- Locations
- ๐บ๐ธ
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
Leniolisib for Immune Dysregulation in PIDs
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT06549114
- Locations
- ๐บ๐ธ
National Institute of Health, Bethesda, Maryland, United States
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 3
- Registration Number
- NCT06249997
- Locations
- ๐ฏ๐ต
Hiroshima University Hospital, Hiroshima, Hiroshima City, Japan
๐ฏ๐ตTokyo Medical And Dental University Hospital, Tokyo, Bunkyo-ku, Japan
Pediatric Patients Aged 1 to 6 Years With APDS
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 16
- Registration Number
- NCT05693129
- Locations
- ๐บ๐ธ
University of California Los Angeles, Los Angeles, California, United States
๐บ๐ธNational Institutes of Health, Bethesda, Maryland, United States
๐บ๐ธThe University of North Carolina, Chapel Hill, North Carolina, United States
Pediatric Patients Aged 4 to 11 Years with APDS
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 15
- Registration Number
- NCT05438407
- Locations
- ๐ฏ๐ต
Institute of Science Tokyo Hospital, Tokyo, Japan
๐ฏ๐ตKyoto University Hospital, Kyoto, Japan
๐บ๐ธUniversity of California Los Angeles, Los Angeles, California, United States
Prevention of Acute Kidney Injury in Patients With NSTEMI
- Conditions
- Non-ST Elevation Myocardial Infarction (NSTEMI)
- Interventions
- Drug: conestat alfa or placebo
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 29
- Registration Number
- NCT04912141
- Locations
- ๐จ๐ญ
Fondazione Istituto Cardiocentro Ticino, Lugano, Switzerland
๐จ๐ญUniversity Hospital Geneva, Geneva, Switzerland
๐จ๐ญUniversity Hospital Basel, Basel, Switzerland
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 38
- Registration Number
- NCT04530136
- Locations
- ๐บ๐ธ
Virtua Marlton Hospital, Marlton, New Jersey, United States
๐บ๐ธVirtua Voorhees Hospital, Voorhees, New Jersey, United States
๐บ๐ธVirtua Memorial Hospital, Mount Holly, New Jersey, United States
Patient Registry to Evaluate the Real-world Safety of Ruconestยฎ
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 152
- Registration Number
- NCT03697187
- Locations
- ๐บ๐ธ
The US Hereditary Angioedema Association, Fairfax, Virginia, United States
Extension to the Study of Efficacy of CDZ173 in Patients with APDS/PASLI
- Conditions
- Activated PI3Kdelta Syndrome (APDS); PASLI Disease
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 37
- Registration Number
- NCT02859727
- Locations
- ๐ท๐บ
Pharming Investigative Site, Moscow, Russian Federation
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
- Conditions
- Hereditary Angioedema
- Interventions
- Biological: Recombinant human C1 inhibitorOther: Placebo
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Pharming Technologies B.V.
- Target Recruit Count
- 32
- Registration Number
- NCT02247739
- Locations
- ๐บ๐ธ
Washington University Division of Allergy and Immunology, Saint Louis, Missouri, United States
๐จ๐ฟFaculty Hospital by St. Anna Brno, Department of clinical Immunology and Allergology, Brno, Czechia
๐ฒ๐ฐPHI University Clinic of Dermatology, Skopje, Macedonia, The Former Yugoslav Republic of